How to Submit an Application

The African Vaccine Acquisition Trust of 7th Floor, Happy World House, 37 Sir William Newton Street, Port-Louis 11328, Mauritius, a centralised negotiating, purchasing, and payment agent incorporated on behalf of the AU Member States and CARICOM Member States for the purchase of COVID-19 vaccines pursuant to the AVAT Framework.

A written claim for compensation completed by an Applicant on the application form approved by and provided by the Administrator, as set forth in Schedule 2 to the Program's Protocol, which must be accompanied by all Supporting Evidence, using the prescribed form in Schedule 3 to the Program’s Protocol.

The supporting evidence, using the form in Schedule 3 to the Program's Protocol, required to evaluate an Application and that shall include:

1. detailed medical documentation from a Registered Health Professional describing the Injury and medical treatment required as a result of the Injury, together with details of any Hospitalization or prolonged Hospitalization, including but not limited to admission and discharge records;
2. a description of the nature, extent, functional impact and prognosis of the Injury, as assessed by the Registered Health Professional.
3. a statement from the Registered Health Professional that the Injury was, in the Registered Health Professional’s opinion, the result of the Vaccine or its administration;
4. certification from a Registered Health Professional of when, where and which Vaccine was administered;
5. in the case of death, a death certificate and any other documentation available from a Registered Health Professional of the cause and manner of death; and
6. any further evidence that the Administrator may deem necessary to adjudicate the Application, and/or Receivable Claim, as applicable, guided, as appropriate, by the Scientific Advisory Committee, the Review Panel, and/or the Appeals Panel.

A resident, a citizen or person within the population of a Participating Member State who claims or in respect of whom it is claimed that he or she has suffered or sustained a Serious Adverse Event which is associated with a Vaccine or its administration, and which, in turn, has resulted in an Injury.

A COVID-19 vaccine received in any Participating Member State through the AVAT Framework that:

1. either (A) has licensure or authorization from a stringent (“functional”) regulatory authority or (B) has received WHO prequalification, following licensure or authorization from a stringent (“functional”) regulatory authority, or (C) has been issued authorization for emergency use based on licensure or authorization by a stringent (“functional”) regulatory authority; and
2. is included in Schedule 1 to the Program's Protocol, as updated from time to time; and
3. has received all required approvals and authorizations for importation, distribution, and use in the relevant Participating Member State; and
4. has not reached its Scope of Coverage Endpoint.

Any healthcare professional, including physicians, surgeons, nurses, midwives, nurse practitioners, physicians’ assistants, psychiatrists, psychiatrists, physical therapists, occupational therapists, dentists, and pharmacists, who is duly licensed or legally authorized to practice the profession in the Participating Member State in which the Patient resides and received the Vaccine, or in the case of birth defects, where the Patient’s mother resides and received the Vaccine.

A serious untoward medical occurrence that (i) is sustained or suffered by a Patient following the administration of a Vaccine, and (ii) results in an Injury, as defined in the Program's Protocol.

The AVAT No Fault Compensation Scheme, as detailed in the Protocol and its Schedules.

ESIS, Inc., the claims Administrator appointed to manage and administer the Program, including, but not limited to, the receipt and registration of Applications, distributing acknowledgements of receipt of Applications, setting financial reserves for Receivable Claims, review of Applications, Supporting Evidence, and other documents to assess receivability, assessing Receivable Claims, and approve or deny, as the case may be, Payment for compensation, in accordance with the terms of the Program's Protocol.

On a per Vaccine basis, the period during which an Applicant may file an Application for compensation under the Program in respect of such Vaccine. The maximum Reporting Period for each Vaccine extends from:

1. the date on which such Vaccine was first put into circulation by the manufacturer within the AVAT Framework, following regulatory approval or an emergency use authorization of such Vaccine by any regulator (as indicated in Schedule 1 to the Program's Protocol); and
2. terminates on the date which is 36 calendar months immediately after the Scope of Coverage Endpoint for such Vaccine (as indicated in Schedule 1 to the Program's Protocol), provided always that the Vaccine was administered before this Vaccine’s Scope of Coverage Endpoint (as defined in Section 2 of the Program's Protocol and indicated in Schedule 1 to the Program's Protocol). See the illustrative diagram of the Reporting Period attached as Schedule 7 to the Program's Protocol. For each Patient, the Reporting Period depends on the date the Vaccine was administered to the Patient. To calculate the Reporting Period that applies to the Patient, the Patient (or a person who is a duly authorized to represent the Patient as provided in part (ii) of the definition of Applicant in the Program's Protocol) needs to:
   1. determine (through Schedule 1 to the Program's Protocol) what is the date of the Scope of Coverage End Point that applies to the Vaccine that was administered to Patient; and
   2. calculate the number of months and days from the vaccination date (i.e. date that the Vaccine was administered to the Patient) until the date of the Vaccine’s Scope of Coverage End Point, and add another 36 months. This establishes the Reporting Period that applies to the Patient.